Cogentix backs Vensica Medical and its needle-free drug delivery system
Cogentix Medical (NASDAQ: CGNT) said today that it invested $2 million in privately-held Vensica Medical and its ultrasound-based, needle-free drug delivery device, VensiCare.
Israel-based Vensica Medical is developing its VensiCare device as a way to deliver botulinum toxin to treat overactive bladder. The company also has IP for the delivery of oncology agents to the bladder, according to Cogentix.
Get the full story at our sister site, Drug Delivery Business News.
The post Cogentix backs Vensica Medical and its needle-free drug delivery system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 28, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Wall Street Beat Cogentix Medical vensicamedical Source Type: news
Tackling bedwetting: ‘Don’t be afraid to talk about it’
Bedwetting, otherwise known as urinary incontinence or enuresis, is fairly common, often embarrassing and sometimes difficult to talk about. It is estimated that about 20 percent of boys and 17 percent of girls, ages 6 to 7 years old have some problem with daytime or nighttime wetting. Still, many kids are reluctant to talk about wetting with parents, friends and teachers. Parents themselves often have a hard time confronting the issue.
The Voiding Improvement Program (VIP) at Boston Children’s Hospital offers a comprehensive approach to bedwetting tailored to each child’s individual needs. “Our program is dri...
Source: Thrive, Children's Hospital Boston - August 7, 2017 Category: Pediatrics Authors: Maureen McCarthy Tags: Health & Wellness bedwetting Dr. Carlos Estrada enuresis Pamela Kelly Voiding Improvement Program Source Type: news
Boston Scientific joins OAB device dev Amphora Medical ’ s $36m Series B
Amphora Medical said today it closed a $35.5 million Series B financing round, led by major medtech player Boston Scientific (NYSE:BSX), with funds slated to support a US pivotal trial of its Selective Bladder Denervation System for treating women with overactive bladder.
Amphora’s Selective Bladder Denervation System is a minimally-invasive, cystopic device which uses targeted ablation to reduce nerve signals responsible for OAB symptoms at their source without harming nerves responsible for normal bladder function, the Minneapolis, Minn.-based company said.
“The closing of this round is an important mileston...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Women's Health Amphora Medical Boston Scientific Source Type: news
Boston Scientific joins in $36M round for Twin Cities med-tech startup
Amphora Medical Inc. is developing a device to treat overactive bladder and will put the capital toward a clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 21, 2017 Category: Biotechnology Authors: Katharine Grayson Source Type: news
Boston Scientific joins in $36M round for Twin Cities med-tech startup
Amphora Medical Inc. is developing a device to treat overactive bladder and will put the capital toward a clinical trial. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 21, 2017 Category: Health Management Authors: Katharine Grayson Source Type: news
The Role of the Female Urinary Microbiota in OAB Symptoms The Role of the Female Urinary Microbiota in OAB Symptoms
New research suggests a possible link between the microbiota of the female urinary tract and overactive bladder symptoms. What are the implications for urine culturing practices?Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2017 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news
MassDevice.com +5 | The top 5 medtech stories for July 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. OrthoSensor raises $6.3m
OrthoSensor raised $6.3 million in a new round of mixed financing, according to an SEC filing posted this week.
Money in the round came from 15 unnamed sources, according to the SEC filing, with the 1st...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Medtronic touts 5-year data on InterStim neuromod device for OAB
Medtronic (NYSE:MDT) today touted 5-year results from the InSite study of its InterStim neuromodulation treatment for overactive bladder syndrome.
InterStim is designed to stimulate the sacral nerve to treat OAB, meaning urinary urge incontinence and/or urgency-frequency. The InSite study enrolled 340 patients, of which 272 were implanted with an InterStim device, comparing treatment with the device with standard drug therapy. The primary safety endpoint was to “demonstrate that the upper bound of the 95% CI for the cumulative five-year rate of adverse events related to the tined lead that require surgery is less th...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Urology Women's Health Medtronic Source Type: news
Axonics adds $21m to Series C round
Axonics Modulation Technologies said today that it put another $21 million in its coffers in the second tranche of a Series C round for its sacral nerve modulation technology in treating overactive bladder syndrome.
The first, $15 million Series C tranche closed in May. The latest, $20.5 million tranche takes Axonics’ total raise to at least $106.1 million, adding to its $32.6 million Series A round and the $38.5 million Series B. The Irvine, Calif.-based company said it plans to use the proceeds on a pivotal study that’s slated to launch late this year.
The Series C second tranche included new investors Gilde ...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
USFDA gives nod to Zydus Cadila's overactive bladder tablets
The drug is used to take care of an overactive bladder and urinary incontinence and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 28, 2017 Category: Pharmaceuticals Source Type: news
Glenmark Pharma's overactive bladder drug gets USFDA nod
According to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 22, 2017 Category: Pharmaceuticals Source Type: news
MassDevice.com +5 | The top 5 medtech stories for May 2, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Advanced Cardiac Therapies lands $45m round led by new PE shop Ajax Health
Ajax Health, the medical device portfolio management company newly formed by KKR and Aisling Capital, led a $45 million round for Advanced Cardiac Thera...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Axonics raises another $15m for U.S. sacral neurostim trial
Axonics Modulation Technologies said today that it put nearly $15 million into its coffers as it readies a pivotal study later this year for its sacral nerve modulation technology in treating overactive bladder syndrome.
The Irvine, Calif.-based company said it hopes to add another $15.5 million to the $14.5 million it pulled in from its Series C round, which involved all of its major backers including Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, Legend Capital, NeoMed Management and “a select group of private individuals.”
“These world-class investors ha...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
Medical News Today: How to treat an overactive bladder with natural remedies
In this article, learn about the symptoms of an overactive bladder, when a doctor should be consulted, and natural remedies to treat an overactive bladder. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 24, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
Medical News Today: Overactive bladder in children: Causes, symptoms, and treatment
Learn about the factors that can lead to an overactive bladder in children. What are the signs and when should treatment be given for this condition? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2017 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news
